A Phase 3 interventional study of Bupivicaine in Obstetrical Complications From Sedation During Parturition, sponsored by New York Presbyterian Brooklyn Methodist Hospital. Withdrawn at 1 site in United States. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2021-10-14.
Sponsored by New York Presbyterian Brooklyn Methodist Hospital · Phase 3, Interventional, and Treatment
Adding TAP block with Bupivacaine may decrease the use of PCA bolus use after caesarean section for pain relief.
Participants in the study will be randomized to TAP block with 0.5% or 0.25% bupivacaine or with placebo (normal saline).
The number of PCA bolus used within 24 hours post cesarean section will be compared between the groups.
New York Presbyterian Brooklyn Methodist Hospital is the lead sponsor of 16 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Healthy pregnant (ASA II) patients presenting for planned Cesarean delivery at New York Methodist Hospital under combined spinal epidural anesthesia
Exclusion Criteria:
Drug Bupivacaine 0.5%
Drug: Bupivicaine
Drug Bupivacaine 0.25%
Drug: Bupivicaine
Saline Normal
Drug: Bupivicaine
Transversus Abdominis Plane (TAP) Block for Post Caesarean Pain
In Patient Controlled analgesia (PCA) system, the patient receives a preset dose of morphine by pressing a button on a computerized pump that is connected to an IV catheter. With PCA the patient may receive a small continuous flow of morphine and add more morphine as needed to provide a more constant level of comfort. In this study, we will compare the number of PCAs used by the participants in each arm
Time frame: The first post operative 24 hours
Decrease in the pain score as measured by Visual Analog Scale (VAS)
Visual Analog Scale (VAS) is a numeric scale to measure the pain intensity from 0 to 10, where 0 = no pain, (1-3) = mild pain, (4-6) = moderate pain, and (7-10) = severe pain. The worst imaginable pain = 10
Time frame: The first post operative 24 hours
This study is withdrawn, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bupivacaine
New York Presbyterian Brooklyn Methodist Hospital